SCHEMBL8090568

SCHEMBL8090568

CC(C)n1cnc(N)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24462192 0.82
SCHEMBL25001285 0.73
SCHEMBL2631872 0.73
SCHEMBL11816135 0.71
SCHEMBL21577857 0.71
SCHEMBL5477196 0.71
SCHEMBL30437993 0.71
SCHEMBL12924661 0.70 HCAR3 (0.36)
SCHEMBL784347 0.69 ADORA1 (0.40)
SCHEMBL23851064 0.69 PIK3CD (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104744491-B Benzo oxazepine * PI3K inhibitor compounds and application method 霍夫曼-拉罗奇有限公司 2017-07-11 CN claimed
CN-102762576-A Benzoxazepine PI3K inhibitor compounds and methods of use HOFFMANN LA ROCHE 2012-10-31 CN claimed
EP-4594309-A1 AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION Genentech Inc. (US) 2025-08-06 EP disclosed
CN-120019049-A Azole modulators of cholesterol biosynthesis and their use for promoting remyelination 基因泰克公司 2025-05-16 CN disclosed
EP-4436974-A1 SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION Genentech, Inc. (US) 2024-10-02 EP disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
WO-2024073662-A1 AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION GENENTECH, INC. (US) 2024-04-04 WO disclosed
US-20240025886-A1 INHIBITORS OF IGF2BP1-RNA BINDING YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2024-01-25 US disclosed
US-20240025886-A1 INHIBITORS OF IGF2BP1-RNA BINDING YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2024-01-25 US disclosed
WO-2023097230-A1 SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION GENENTECH, INC. (US) 2023-06-01 WO disclosed
US-20230157290-A1 ALKENE-CONTAINING CARBOXYLATE COMPOUND AND USE THEREOF JIANGSU YANGNONG CHEMICAL CO., LTD (CN) 2023-05-25 US disclosed
US-20230157290-A1 ALKENE-CONTAINING CARBOXYLATE COMPOUND AND USE THEREOF JIANGSU YANGNONG CHEMICAL CO., LTD (CN) 2023-05-25 US disclosed
US-20230014226-A1 NEW COMPOUNDS AND METHODS BENEVOLENTAI BIO LIMITED (GB) 2023-01-19 US disclosed
WO-2021203011-A1 RIP1K INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2021-10-07 WO disclosed
CN-104744491-B Benzo oxazepine * PI3K inhibitor compounds and application method 霍夫曼-拉罗奇有限公司 2017-07-11 CN disclosed
CN-102762576-A Benzoxazepine PI3K inhibitor compounds and methods of use HOFFMANN LA ROCHE 2012-10-31 CN disclosed
WO-2009014730-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS IDENIX PHARMACEUTICALS, INC. (US) 2009-01-29 WO disclosed